BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

Paige’s $100 million series C suggests investor enthusiasm for cancer diagnostics extends beyond liquid biopsy and includes machine-learning tools for image-based pathology.  The New York-based company will use the funds to speed development of clinical applications,...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

...against new protein targets. Verdine and Klausner declined to comment on Hexagon. Existing LifeMine investors GV, WuXi Healthcare Ventures...
...UniversityCorporate partners: N/ANumber of employees: ~100Funds raised: $120 millionInvestors: Rick Klausner, Milky Way Investments, GV, WuXi Healthcare Ventures...
BioCentury | Jan 9, 2021
Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

...who was a senior adviser at Frazier Healthcare Ventures...
BioCentury | Jan 8, 2021
Finance

Crossovers back Affinivax in $236M round as more pipeline vaccines move toward clinic

...Joining them were existing investors Viking Global Investors, Bain Capital Life Sciences and Ziff Capital Healthcare Ventures. Paul...
BioCentury | Jan 7, 2021
Finance

Weill Cornell spinout Lexeo raises $85M series A to develop clinical gene therapy programs

...NYSE:PFE) during a 12-year stint with the pharma; and Chairman Steven Altschuler, the managing director of healthcare ventures...
BioCentury | Dec 21, 2020
Finance

Dec. 21-23 Financial Quick Takes: Venture rounds for SomaLogic, ONL; plus Jacobio’s HK listing, Cullinan, Gracell and Zhaoke file for IPOs, and more

...in the second close include Janus Henderson Investors, Redmile Group, Logos Capital, Revelation Partners, Ziff Capital Healthcare Ventures...
BioCentury | Nov 14, 2020
Finance

Jeito adds dry powder to invest in European innovation

...who was a senior adviser at Frazier Healthcare Ventures...
BioCentury | Sep 15, 2020
Finance

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

...organization of Johnson & Johnson (NYSE:JNJ); Annette Clancy, who was a senior adviser at Frazier Healthcare Ventures...
BioCentury | Sep 10, 2020
Finance

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

Korro Bio’s $91.5 million series A round opens the door to new leadership for the Atlas-built RNA editing company, which has been led by Executive Chairman Nessan Bermingham since its launch in 2018. “With the series...
BioCentury | May 13, 2020
Emerging Company Profile

QurAlis taking three ALS programs toward clinic with $42M series A

After launching with a modest seed round in 2018, neurology company QurAlis is driving toward the clinic with a $42 million series A round to fund development of three therapies to treat amyotrophic lateral sclerosis...
Items per page:
1 - 10 of 534
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

Paige’s $100 million series C suggests investor enthusiasm for cancer diagnostics extends beyond liquid biopsy and includes machine-learning tools for image-based pathology.  The New York-based company will use the funds to speed development of clinical applications,...
BioCentury | Jan 13, 2021
Emerging Company Profile

LifeMine taps fungal genomes for new drug candidates

...against new protein targets. Verdine and Klausner declined to comment on Hexagon. Existing LifeMine investors GV, WuXi Healthcare Ventures...
...UniversityCorporate partners: N/ANumber of employees: ~100Funds raised: $120 millionInvestors: Rick Klausner, Milky Way Investments, GV, WuXi Healthcare Ventures...
BioCentury | Jan 9, 2021
Finance

Closing year with flurry of deals, Tordjman’s Jeito fine-tunes its investment strategy

...who was a senior adviser at Frazier Healthcare Ventures...
BioCentury | Jan 8, 2021
Finance

Crossovers back Affinivax in $236M round as more pipeline vaccines move toward clinic

...Joining them were existing investors Viking Global Investors, Bain Capital Life Sciences and Ziff Capital Healthcare Ventures. Paul...
BioCentury | Jan 7, 2021
Finance

Weill Cornell spinout Lexeo raises $85M series A to develop clinical gene therapy programs

...NYSE:PFE) during a 12-year stint with the pharma; and Chairman Steven Altschuler, the managing director of healthcare ventures...
BioCentury | Dec 21, 2020
Finance

Dec. 21-23 Financial Quick Takes: Venture rounds for SomaLogic, ONL; plus Jacobio’s HK listing, Cullinan, Gracell and Zhaoke file for IPOs, and more

...in the second close include Janus Henderson Investors, Redmile Group, Logos Capital, Revelation Partners, Ziff Capital Healthcare Ventures...
BioCentury | Nov 14, 2020
Finance

Jeito adds dry powder to invest in European innovation

...who was a senior adviser at Frazier Healthcare Ventures...
BioCentury | Sep 15, 2020
Finance

Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital

...organization of Johnson & Johnson (NYSE:JNJ); Annette Clancy, who was a senior adviser at Frazier Healthcare Ventures...
BioCentury | Sep 10, 2020
Finance

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

Korro Bio’s $91.5 million series A round opens the door to new leadership for the Atlas-built RNA editing company, which has been led by Executive Chairman Nessan Bermingham since its launch in 2018. “With the series...
BioCentury | May 13, 2020
Emerging Company Profile

QurAlis taking three ALS programs toward clinic with $42M series A

After launching with a modest seed round in 2018, neurology company QurAlis is driving toward the clinic with a $42 million series A round to fund development of three therapies to treat amyotrophic lateral sclerosis...
Items per page:
1 - 10 of 534